<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39349061</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-1426</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal for immunotherapy of cancer</Title><ISOAbbreviation>J Immunother Cancer</ISOAbbreviation></Journal><ArticleTitle>Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e009799</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2024-009799</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borderline resectable NSCLC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-arm, phase-II trial enrolled operable T3-4N0-2 patients with NSCLC without oncogenic drivers. Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT, IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later. Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy. Resections were 6 weeks post-radiotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a total of 30 patients in the intention-to-treat (ITT) population, grades 3-4 treatment-related adverse events (TRAEs) occurred in 70%, one TRAE grade 5 late-onset pneumonitis on day 96 post-surgery (1/30, 3.3%) occurred, and one non-TRAE COVID-19 death (1/30, 3.3%). pCR and MPR were achieved in 50% (15/30) and 63% (19/30) of the ITT; and in 58% (15/26) and 73% (19/26) of the 26 patients who underwent surgery, respectively. Postoperative melanoma was seen in one non-pCR patient. The R0 rate was 100% (26/26), and no patient failed surgery due to TRAEs. In peripheral blood, proliferative CD8<sup>+</sup> T cells were increased, while proliferative regulatory T cells (Tregs) were not. On-treatment, pCR-positives had higher CD8<sup>+</sup>CD39<sup>+</sup> T cells and lower HLA-DR<sup>+</sup> Tregs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neoadjuvant IPI-NIVO-CRT in T3-4N0-2 NSCLC showed acceptable safety with pCR and MPR in 58% and 73% of operated patients, respectively. No patient failed surgery due to TRAEs.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT04245514.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bahce</LastName><ForeName>Idris</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-1111-608X</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC Location VUmc, Amsterdam, Noord-Holland, Netherlands i.bahce@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickhoff</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneiders</LastName><ForeName>Famke L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veltman</LastName><ForeName>Joris</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heineman</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemi</LastName><ForeName>Sayed M S</ForeName><Initials>SMS</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrijmoet</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houda</LastName><ForeName>Ilias</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulas</LastName><ForeName>Ezgi B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-1551-738X</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Joyce</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Ven</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwhuis</LastName><ForeName>Natalja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijboom</LastName><ForeName>Lilian J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oprea-Lager</LastName><ForeName>Daniela E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Maldegem</LastName><ForeName>Febe</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2544-544X</Identifier><AffiliationInfo><Affiliation>Molecular Cellular Biology and Immunology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fransen</LastName><ForeName>Marieke F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0003-3036-8618</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Gruijl</LastName><ForeName>Tanja D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radonic</LastName><ForeName>Teodora</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senan</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3995-2204</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Amsterdam UMC Locatie VUmc, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Noord-Holland, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04245514</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Immunother Cancer</MedlineTA><NlmUniqueID>101620585</NlmUniqueID><ISSNLinking>2051-1426</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074324">Ipilimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074324" MajorTopicYN="Y">Ipilimumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077594" MajorTopicYN="Y">Nivolumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Ipilimumab</Keyword><Keyword MajorTopicYN="N">Nivolumab</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword></KeywordList><CoiStatement>Competing interests: The authors have disclosed the following conflicts of interest: DEO-L received grants from Janssen and Curium, honoraria from EANM, EAU, ESMO, and Curium, travel support from EANM, ESMO, EAU, and Bayer, and serves on a Bayer advisory board. CD received institutional fees for advisory roles with BMS, AstraZeneca, and MSD. SMSH has research contracts with several pharmaceutical companies and received honoraria from Janssen. IB’s institution received support from BMS, AstraZeneca, and Boehringer Ingelheim, and he received honoraria from AstraZeneca, MSD, and BMS. FLS received a research grant from ViewRay and honoraria from AstraZeneca. SS’s institution received grants from Varian, ViewRay, and AstraZeneca; he received consulting fees and honoraria from AstraZeneca and MSD, and serves on advisory boards for AstraZeneca and MSD. TDdG’s institution received grants from Idera Pharmaceuticals, consulting fees from LAVA Therapeutics and Mendus, and she holds stock in LAVA Therapeutics. All other authors have declared no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349061</ArticleId><ArticleId IdType="pmc">PMC11448277</ArticleId><ArticleId IdType="doi">10.1136/jitc-2024-009799</ArticleId><ArticleId IdType="pii">jitc-2024-009799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. doi: 10.1002/ijc.31937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31937</ArticleId><ArticleId IdType="pubmed">30350310</ArticleId></ArticleIdList></Reference><Reference><Citation>Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21. doi: 10.1093/annonc/mdx222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx222</ArticleId><ArticleId IdType="pubmed">28881918</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022;40:1356–84. doi: 10.1200/JCO.21.02528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02528</ArticleId><ArticleId IdType="pubmed">34936470</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Meerbeeck JP, Van Schil PEY, Senan S, et al. Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2007;2:1138–9. doi: 10.1097/JTO.0b013e31815ba815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e31815ba815</ArticleId><ArticleId IdType="pubmed">18090593</ArticleId></ArticleIdList></Reference><Reference><Citation>Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86. doi: 10.1016/S0140-6736(09)60737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60737-6</ArticleId><ArticleId IdType="pmc">PMC4407808</ArticleId><ArticleId IdType="pubmed">19632716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ünal S, Winkelman JA, Heineman DJ, et al. Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors. JTO Clin Res Rep. 2023;4:100475. doi: 10.1016/j.jtocrr.2023.100475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtocrr.2023.100475</ArticleId><ArticleId IdType="pmc">PMC10031478</ArticleId><ArticleId IdType="pubmed">36969550</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricard J, Filaire M, Vergé R, et al. Multimodality therapy for lung cancer invading the chest wall: A study of the French EPITHOR database. Lung Cancer (Auckl) 2023;181:107224. doi: 10.1016/j.lungcan.2023.107224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2023.107224</ArticleId><ArticleId IdType="pubmed">37156211</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt WEE, Pöttgen C, Gauler TC, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) J Clin Oncol. 2015;33:4194–201. doi: 10.1200/JCO.2015.62.6812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.62.6812</ArticleId><ArticleId IdType="pubmed">26527789</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickhoff C, Hartemink KJ, Kooij J, et al. Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes? Ann Oncol. 2017;28:185. doi: 10.1093/annonc/mdw449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdw449</ArticleId><ArticleId IdType="pubmed">27687305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerfolio RMJ, Bryant AS, Jones VL, et al. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival☆. Eur J Cardiothorac Surg. 2009;35:718–23. doi: 10.1016/j.ejcts.2008.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2008.12.029</ArticleId><ArticleId IdType="pubmed">19233668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascone T, William WN, Jr, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504–14. doi: 10.1038/s41591-020-01224-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01224-2</ArticleId><ArticleId IdType="pmc">PMC8818318</ArticleId><ArticleId IdType="pubmed">33603241</ArticleId></ArticleIdList></Reference><Reference><Citation>Formenti SC, Rudqvist N-P, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845–51. doi: 10.1038/s41591-018-0232-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0232-2</ArticleId><ArticleId IdType="pmc">PMC6286242</ArticleId><ArticleId IdType="pubmed">30397353</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:39–51. doi: 10.1016/j.jtho.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2015.09.009</ArticleId><ArticleId IdType="pubmed">26762738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickhoff C, Senan S, Schneiders FL, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20:764. doi: 10.1186/s12885-020-07263-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-020-07263-9</ArticleId><ArticleId IdType="pmc">PMC7427738</ArticleId><ArticleId IdType="pubmed">32795284</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) Ann Oncol. 2018;29:1853–60. doi: 10.1093/annonc/mdy218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy218</ArticleId><ArticleId IdType="pmc">PMC6096736</ArticleId><ArticleId IdType="pubmed">29982279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastings K, Yu HA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019;30:1311–20. doi: 10.1093/annonc/mdz141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz141</ArticleId><ArticleId IdType="pmc">PMC6683857</ArticleId><ArticleId IdType="pubmed">31086949</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–35. doi: 10.1158/2159-8290.CD-18-0099/333370/AM/STK11-LKB1-MUTATIONS-AND-PD-1-INHIBITOR-RESISTANCE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-18-0099/333370/AM/STK11-LKB1-MUTATIONS-AND-PD-1-INHIBITOR-RESISTANCE</ArticleId><ArticleId IdType="pmc">PMC6030433</ArticleId><ArticleId IdType="pubmed">29773717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321–8. doi: 10.1093/annonc/mdz167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz167</ArticleId><ArticleId IdType="pmc">PMC7389252</ArticleId><ArticleId IdType="pubmed">31125062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Wang X, Chi Z, et al. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Front Immunol. 2021;12:691032. doi: 10.3389/fimmu.2021.691032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.691032</ArticleId><ArticleId IdType="pmc">PMC8289467</ArticleId><ArticleId IdType="pubmed">34290710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortekaas KE, Santegoets SJ, Sturm G, et al. CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer. Cancer Immunol Res. 2020;8:1311–21. doi: 10.1158/2326-6066.CIR-20-0270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0270</ArticleId><ArticleId IdType="pubmed">32759363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascone T, Leung CH, Weissferdt A, et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023;29:593–604. doi: 10.1038/s41591-022-02189-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02189-0</ArticleId><ArticleId IdType="pmc">PMC10033402</ArticleId><ArticleId IdType="pubmed">36928818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pataer A, Weissferdt A, Correa AM, et al. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep. 2022;3:100420. doi: 10.1016/j.jtocrr.2022.100420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtocrr.2022.100420</ArticleId><ArticleId IdType="pmc">PMC9646962</ArticleId><ArticleId IdType="pubmed">36389133</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencio-Pulla M, Spicer J, Taube JM, et al. Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816. J C O. 2022;40:LBA8511. doi: 10.1200/JCO.2022.40.17_suppl.LBA8511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.17_suppl.LBA8511</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz-Ares L, Ciuleanu T-E, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211. doi: 10.1016/S1470-2045(20)30641-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30641-0</ArticleId><ArticleId IdType="pubmed">33476593</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Lee J-S, Ciuleanu T-E, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227. JCO. 2023;41:1200–12. doi: 10.1200/JCO.22.01503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.01503</ArticleId><ArticleId IdType="pmc">PMC9937094</ArticleId><ArticleId IdType="pubmed">36223558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J C O. 2019;37:8504. doi: 10.1200/JCO.2019.37.15_suppl.8504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.8504</ArticleId></ArticleIdList></Reference><Reference><Citation>William WN, Jr, Pataer A, Kalhor N, et al. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013;8:222–8. doi: 10.1097/JTO.0b013e3182774108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e3182774108</ArticleId><ArticleId IdType="pmc">PMC3549050</ArticleId><ArticleId IdType="pubmed">23287849</ArticleId></ArticleIdList></Reference><Reference><Citation>Senan S, Brade A, Wang L-H, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:953–62. doi: 10.1200/JCO.2015.64.8824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.64.8824</ArticleId><ArticleId IdType="pubmed">26811519</ArticleId></ArticleIdList></Reference><Reference><Citation>Liveringhouse CL, Latifi K, Asous AG, et al. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023;116:837–48. doi: 10.1016/j.ijrobp.2023.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2023.01.006</ArticleId><ArticleId IdType="pubmed">36657497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu TC, Stube A, Felix C, et al. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023;117:118–22. doi: 10.1016/j.ijrobp.2023.03.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2023.03.069</ArticleId><ArticleId IdType="pubmed">37023987</ArticleId></ArticleIdList></Reference><Reference><Citation>Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet. 2021;398:1344–57. doi: 10.1016/S0140-6736(21)02098-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02098-5</ArticleId><ArticleId IdType="pubmed">34555333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC) J C O. 2021;39:8500. doi: 10.1200/JCO.2021.39.15_suppl.8500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2021.39.15_suppl.8500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>